IMforte: Superior quality-adjusted survival with lurbinectedin plus atezolizumab maintenance in treatment-naïve patients with ES-SCLC

CHICAGO 2026

Lung, Respiratory and Thoracic Cancer

Jazz EMERGE 402: Final primary analysis supports real-world effectiveness of lurbinectedin in patients with previously treated ES-SCLC

Lung, Respiratory and Thoracic Cancer

Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19)

Eur J Cancer

Addeo A, Dietrich D, Mach N, Mark MT, Joerger M, Froesch P, Imbimbo M, König D, Fernandez E, Patzen A, Vees H, Picardi C, Früh M

doi: 10.1016/j.ejca.2025.116138

ASH 2025

Leukemia

LBA-3: BRUIN CLL-313: Pirtobrutinib is superior to bendamustine plus rituximab in treatment-naïve CLL/SLL

Lung, Respiratory and Thoracic Cancer

Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO

JTO Clin Res Rep

Falchero L, Amrane K, Godbert B, Leterre B, Madelaine J, Fournel P, Mascaux C, Raimbourg J, Schneider S, Swalduz A, Veillon R, Langlais A, Missy P, Morin F, Westeel V, Girard N

doi: 10.1016/j.jtocrr.2026.100964

Lung, Respiratory and Thoracic Cancer

Lurbinectedin for extensive stage - small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes

Lung Cancer

Krayim B, Shalata W, Bar J, Moskovitz M, Rotem O, Urban D, Sorotsky HG, Kian W, Hanovich E, Marie R, Mann S, Gillis R, Basel A, Kornev G, Asna N, Peled N, Roisman LC

doi: 10.1016/j.lungcan.2025.108598

Gynecologic Cancer

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)

J Natl Cancer Inst

Joly F, Anota A, Chabaud S, Cropet C, Priou F, Harter P, Pignata S, Palacio I, Petru E, Kobayashi H, Vergote I, Parma G, Mäenpää J, Raymond E, Ataseven B, Pisano C, Lainez N, Tsibulak I, Yonemori K, Vuylsteke P, Lapresa MT, Mirza MR, Bouchaert P, Buderath P, Lorusso D, Herrero A, Eberst L, Burges A, Scambia G, Ortega E, Guillemet C, Pujade-Lauraine E, Kurtz JE, Ray-Coquard I

doi: 10.1093/jnci/djag122

ASH 2025

Leukemia

AMPLIFY: Manageable safety profile of acalabrutinib plus venetoclax with or without obinutuzumab in patients with treatment-naïve CLL

Lung, Respiratory and Thoracic Cancer

Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1

J Thorac Oncol

Peters S, Regan MM, Paz-Ares LG, Reck M, Borghaei H, O'Byrne KJ, Brahmer JR, Penrod JR, Li J, Tracy L, Yuan Y, Bushong J, Lee A, Eccles LJ, Ray S, Ramalingam SS

doi: 10.1016/j.jtho.2025.05.019

CHICAGO 2026

Genitourinary Cancer

Related content

Jazz EMERGE 402: Final primary analysis supports real-world effectiveness of lurbinectedin in patients with previously treated ES-SCLC

Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19)

LBA-3: BRUIN CLL-313: Pirtobrutinib is superior to bendamustine plus rituximab in treatment-naïve CLL/SLL

Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZO

Lurbinectedin for extensive stage - small cell lung cancer (ES-SCLC): real world response patterns and survival outcomes

Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)

AMPLIFY: Manageable safety profile of acalabrutinib plus venetoclax with or without obinutuzumab in patients with treatment-naïve CLL

Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1

POTOMAC: Durvalumab plus BCG continued to show no OS detriment with no major impact on QoL in BCG-naïve patients with high-risk NMIBC